[{"orgOrder":0,"company":"Acesion Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Positive Phase 2 Data from Atrial Fibrillation Clinical Trial \u2013 Primary Endpoint Met","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Not Applicable","leadProduct":"AP30663","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Acesion Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Acesion Pharma \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Acesion Ph.."},{"orgOrder":0,"company":"Acesion Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acesion Pharma Announces Positive Pre-Clinical Data for AP31969","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"AP31969","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Acesion Pharma","amount2":0,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Acesion Pharma \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Acesion Ph.."},{"orgOrder":0,"company":"Acesion Pharma","sponsor":"Canaan","pharmaFlowCategory":"D","amount":"$47.6 million","upfrontCash":"Undisclosed","newsHeadline":"Acesion Pharma Closes Oversubscribed \u20ac45M Series B Financing Round to Advance Development of Novel Therapy for Atrial Fibrillation","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","year":"2023","type":"Series B Financing","leadProduct":"AP31969","moa":"","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"IND Enabling","graph3":"Acesion Pharma","amount2":0.050000000000000003,"therapeuticAreaNew":"Cardiology\/Vascular Diseases","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Cardiovascular Diseases","productSubType":"","amount2New":0.050000000000000003,"dosageForm":"Tablet","sponsorNew":"Acesion Pharma \/ Canaan","highestDevelopmentStatusID":"5","companyTruncated":"Acesion Ph.."}]

Find Clinical Drug Pipeline Developments & Deals by Acesion Pharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Details : The financing will be used to advance the clinical development of AP31969, an SK ion channel inhibitor optimised for chronic oral treatment of atrial fibrillation.

                          Product Name : AP31969

                          Product Type : Small molecule

                          Upfront Cash : Undisclosed

                          September 26, 2023

                          Lead Product(s) : AP31969

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Preclinical

                          Partner/Sponsor/Collaborator : Canaan

                          Deal Size : $47.6 million

                          Deal Type : Series B Financing

                          blank

                          02

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Details : AP31969 is the second-generation oral SK ion channel inhibitor, which is being developed for chronic oral maintenance treatment to prevent AF recurrence.

                          Product Name : AP31969

                          Product Type : Small molecule

                          Upfront Cash : Not Applicable

                          May 15, 2023

                          Lead Product(s) : AP31969

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : IND Enabling

                          Partner/Sponsor/Collaborator : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Details : AP30663 is a first-in-class SK ion channel inhibitor for conversion of AF to normal sinus rhythm. It is being developed for the treatment of atrial fibrillation.

                          Product Name : AP30663

                          Product Type : Small molecule

                          Upfront Cash : Not Applicable

                          March 14, 2023

                          Lead Product(s) : AP30663

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase II

                          Partner/Sponsor/Collaborator : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank